{"name":"Napo Pharmaceuticals, Inc.","slug":"napo-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"Napo Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of novel anti-diarrheal agents. The company's lead product, Mytesi (crofelemer), is approved for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxQUm1MV0p5RlZZWTdueEtmeUhXM1FSTGpBQUdrR2U5M2VIcDVuYmlSdU0zRkMyeHRySGY5U0YzNkpUNXlNWmpyU1FubjFuc1lVQlRmYkdkR3c1cVVqWnl0QXdZWHRlRUNFMko3STJPZ0pUY0lDdUdkdjgwR1JOUWc5bW5QWlVndzJSTWhKNm9KTXdyNXM4VDgzWWNpS2FCRjNWbWN2QU9CaDJzV0NrZGM1UEFxQ2U1TXlYTDFMeGlUVnM3QXpTNUtRZnRsR2w3S05teExhV20xZ0JtdTNRb29WeWdvLTk?oc=5","date":"2026-04-05","type":"pipeline","source":"ACCESS Newswire","summary":"Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress - ACCESS Newswire","headline":"Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Cong","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQMVVZZkF6VmhqVkZEMTkxUmNoU1lqd1h1NnEzVXJONUhvU3lYTF94aHFHaERPUjNrQ1pjdm5SOUhkWXFJOEV3LTNNSWNhZ1RlNmlIT0gwbTBvYktJODc1bkdlTkNiVVJNa2UwOEI3TG8zRmljRTI1Nk1YdlkyVUVoc2dOWjlmMXhuTFJKc3hsdDlfVm92OTN5Mzh2dGtuMlNDQkxCMndiaThPMWhuV25LUzhWVE5DQ29udWc?oc=5","date":"2026-04-02","type":"trial","source":"Stock Titan","summary":"Children needing IV nutrition cut support 12%-37% in crofelemer study - Stock Titan","headline":"Children needing IV nutrition cut support 12%-37% in crofelemer study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwJBVV95cUxONHQ0cTVYd0F3ZHF6dC1WWXd5R2lRSkwzZTJrQnVtUjMwdnJoNEZLNWZHdjRtSEtoR21HTlZjbzZxbFoxcE4ybHdwVUo4YVVBaFVzVk9kLWVGclBMQkIxcWpFRTNZREp3SDBhTFAwZjlTY3I1SGpma1hOc3NZZ2pwNm5YazNlQlV5NHVKdVpERjJFMDZ1bHVXZnV1N0xiNDJwV21XRjBoV05LTFVaSzVZMVFqLTNzZHhfdGpIbHZnV05Jd3oyWFRNYWFERDU5czdFTnRXN1p2X3dNR2M1LWZscEd1ZVVwanpnM056SWNJM2lnQmpGWDF1MDUxY3NuUjUxT2RlSGNTeXZjR0Y1YUJkTnJSRm1oUExYZDFxOFZKb2R3SFd4ekNZNkNyNkFsY3ZPbGtDMXpaWWRiNzg?oc=5","date":"2026-03-16","type":"trial","source":"FinanzNachrichten.de","summary":"Jaguar Health, Inc.: Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Initiates Preclinical Study of Coca for Appetite Suppression - FinanzNachrichten.de","headline":"Jaguar Health, Inc.: Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Initiates Preclin","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxPdU1PYjl4QVAtVG5qUHNHUkdlVDM4dnNyOGF1ZnBnWEFmTHc2VTBFY0hLdWJ2V0ZnaFVYRFVWV3dJZWo4QkRtZkJfeDFiUUdydE91eUN6eTc1Z0NZM1FoVEVGX0FweW1MaUN4UmhOeFRwUmxqMTlsVTIwd1VKUnNzMFU4VF9IcHpBM0xoNXFrUm9UN2lhYm5lblgtMS0xZnhDRVZzTVBvMmQxRzIwWEV4Y0xDdjY0dDM0MkFxSUw3YzVURlA4Q1VjWjFRQzg0SVhjUHJnLXo4VUNJZnRpcUVlMm5KR3I?oc=5","date":"2026-03-03","type":"pipeline","source":"ACCESS Newswire","summary":"Jaguar Health Secures an Additional $3 Million Payment from Future Pak for Mytesi and Canalevia-CA1 - ACCESS Newswire","headline":"Jaguar Health Secures an Additional $3 Million Payment from Future Pak for Mytesi and Canalevia-CA1","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxNaHNhOWVBVF9IM3A5emphME1jVHlBdkd1b0hzTTZVeDVCNjBmbzVZcDM2UGFwQlVVU1FWUlc2elVOdWZYanhMT21BWHNoS2dWeEY5NEFoTmtWbGpMbHpTSWlQa2RpRVFFYzNxTmhQRzhkSTFPWkhOY1p4a3lVaXBGNVduSFdiS05FcE9sXzBtUHVjZnlUYUMybkdSQTZrc3BwdEVvTVJPcEtVVzFITjhNQlAyVEpGbUtHZGlMS2hlYXhsUW90V3pZbkJMUTAzQWhzVTFOX2JKaTBjcXB5TXIwNGlRWQ?oc=5","date":"2026-01-12","type":"deal","source":"ACCESS Newswire","summary":"Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million - ACCESS Newswire","headline":"Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxPWi1ucl9aOTJqd3pacnIzMWZ1eHNWQ0tRRFl3SzNJQUxhQV9hME44SzVRcnJsSlFiWl9mT3FXRVVlTHFqSXU3dVQ3YkMwdE9RcE9kc2V1MklwdklBSkRBTXowRVlQUEhGM2w5ZWZnYmNJbVNrVFcwY2UxQVJVX0dvd1NxVTJZSDNRTjhYVXRGa2xaQWVOOVlVTEJrem9UZkhtQUY2U1JOM19BN0hTU3V5YTVZY185eG40cGNmS0x2OERVdG4wLWMyVHF0dmk1TVFqQkFJcHY1cmgzTnNnZGlocVJn?oc=5","date":"2026-01-05","type":"deal","source":"ACCESS Newswire","summary":"Knight Therapeutics and Jaguar Health Announce Strategic Partnership - ACCESS Newswire","headline":"Knight Therapeutics and Jaguar Health Announce Strategic Partnership","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwJBVV95cUxOZUk5cFkzUGR6aUpPSHZCdWNUR3BQMGFiUGo1VWNMaURQeEs1b2w5R3kxaEtDWDhMcEp6NEdzTW5WazdxWXN1NGdTamkzUFBQVEZ4WFpORFY1ZVZERXA1bU45V21KSkFORHdENEM4R05NdmkyMHdhT3dEYVFyS2lEQWRtWHdCUkxKNnQ1VnRoMXZMckhiZ2xPek41WU5GTEljRm1KdmUzRVNVY2hXcmFqU0FKaUdXcTdBWkNUenk5YlZkVHQ5Nzc4QU8tSEpQbXRSRnFjV281SlgxaEJRMjRwZjVMTG1YMEEtall6cXA0dWxZS2FENmNvLXNEdWF1NjY4aGVhYUl2RlBlMkV3TmVEVFk0VW5yRm00V0xzNHVHeUQ3MEEzcG55bFRzaEotYk9SdHMwWVFFWTd6VENVWWRsQ2M2VQ?oc=5","date":"2025-11-24","type":"pipeline","source":"PR Newswire","summary":"Short Bowel Syndrome Market to Register Stunning Growth at a CAGR of 5% During the Forecast Period (2025-2034) Owing to the Launch of Novel GLP-2 Analogues | DelveInsight - PR Newswire","headline":"Short Bowel Syndrome Market to Register Stunning Growth at a CAGR of 5% During the Forecast Period (2025-2034) Owing to ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNOE12dVhkUkdWbTRXb2E1ODRSTTRNMUo2VThJZ1B0YlVHVlhYb3phM1RfQVVJNVFQcEZwT3h0OGVnSTZCWlhNOGNmZXNUUlRQMXJkSzkzSkdyLVRsRUNLVjN6UC1iRUxJSk5wT0FqNk9FcUlUY29GZnJORkZRRjQyUC1hRmhzWkR3b19oY1ZYRHBpbVJYYnQ1U2lESS12MkJxVENOaw?oc=5","date":"2025-11-24","type":"pipeline","source":"moomoo.com","summary":"Short Bowel Syndrome Market to Register Stunning Growth at a CAGR of 5% During the Forecast Period (2025-2034) Owing to the Launch of Novel GLP-2 Analogues | DelveInsight - moomoo.com","headline":"Short Bowel Syndrome Market to Register Stunning Growth at a CAGR of 5% During the Forecast Period (2025-2034) Owing to ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxPUXBXZ1BzSEgwOWlYcUYxUVFuU1dDTmNnRnExd294VE9kRU1SN3o1d0J0MWVTS1hycEVfMzdlT1hxakd6eF9DbHJuZmNaMXNBOWF5cVd2cW9hSmtwSDBwYjFxalRyQV9TazAyeVpoaGxPUFB4cFYtN1BzMGszSURUOVVyWUVhMTlpZTQ2SHVqOUdQV2M5VVg5eExiVGRoeDhBMUF5RzhWUlM0S0lzY0FZbW1MRVBpaGJsWW1HX2lHNUQ5NFU2RFFOZGlybDk2ZGRNTklkYzY3Sml6eDVKUFEzUjFuNUI?oc=5","date":"2025-04-27","type":"pipeline","source":"ACCESS Newswire","summary":"Jaguar Health Appoints Robert J. Griffing Chief Commercialization Officer of Jaguar Subsidiary Napo Pharmaceuticals - ACCESS Newswire","headline":"Jaguar Health Appoints Robert J. Griffing Chief Commercialization Officer of Jaguar Subsidiary Napo Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5RRC1OT1dJRUJrdkNLbEthclhXUDBUTVNaTTF1d0ZpbjhKSFVOc3VmdmhkbG9NbFJjUnNVV1JKT2NCeWFtYW5kSXVvUDJubFFZeXA4?oc=5","date":"2025-04-24","type":"pipeline","source":"Stock Titan","summary":"JAGX Stock Price, News & Analysis - Stock Titan","headline":"JAGX Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxQR2lUaVdjXzJoc2RaYXpXeFB4TUdvQUpaNjBpazdOM01uVzN1ZkpEQWJJNFkwZ3pua25mWkpvUm4zdEhnbmNTU1pRVzNrWmVoNXVlb0c5VnZCSnFBajdkVU4yTWxPeU9lRUFEa2ViODVXdTAwZkUyUDZTeXNIZVcyMDJCQ21ROVhobkMyS1I1ZVJjNnZMNHIxV09vRU9uWHlsRXh6WFFYUlNnWkF2RlE?oc=5","date":"2021-11-01","type":"pipeline","source":"Life Science Leader","summary":"Jaguar Health's Lisa Conte — An Entrepreneurial Ascent Like No Other - Life Science Leader","headline":"Jaguar Health's Lisa Conte — An Entrepreneurial Ascent Like No Other","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPUGYwdG9pbXpxNWZNZHRsQUllRGpBamZCMzBGajRoSEx2UkNWeV9lbEh1bjBKdVFiRkZ3akpLYkhEdDdQaHJMOGhtT0VkMjAwcXpTNG5xaUJTckZmRXR6STFhcTlLVE9SZ091UTdJeVZ2S2tfdkpfaVNTM29OR25VZ2JndEF3cWk1ay1xQ0RxbHpOMHhCSXc?oc=5","date":"2017-03-01","type":"pipeline","source":"BioPharma Dive","summary":"Napo amps up sales force for AIDS anti-diarrheal - BioPharma Dive","headline":"Napo amps up sales force for AIDS anti-diarrheal","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}